Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination-Reference-Cited by-同舟云学术

Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination

Published:2021-08-07 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

North Crystal M¹²,Barczak Amy¹²³,Goldstein Robert H¹²,Healy Brian C²⁴,Finkelstein Dianne M²⁴,Ding Delaney D¹,Kim Andy⁵,Boucau Julie³,Shaw Bennett¹,Gilbert Rebecca F¹,Vyas Tammy¹,Reynolds Zahra¹,Siddle Katherine J⁶,MacInnis Bronwyn L⁶,Regan James⁵,Flynn James P⁵,Choudhary Manish C²⁵,Vyas Jatin M¹²,Laskowski Karl⁵,Dighe Anand S²⁷,Lemieux Jacob E¹²,Li Jonathan Z²⁵,Baden Lindsey R²⁵,Siedner Mark J¹²,Woolley Ann E²⁵,Sacks Chana A¹²

Affiliation:

1. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

2. Harvard Medical School, Boston, Massachusetts, USA

3. The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA

4. Department of Biostatistics, Massachusetts General Hospital, Boston, Massachusetts, USA

5. Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

6. The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA

7. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA

Abstract

Abstract The impact of coronavirus disease 2019 vaccination on viral characteristics of breakthrough infections is unknown. In this prospective cohort study, incidence of severe acute respiratory syndrome coronavirus 2 infection decreased following vaccination. Although asymptomatic positive tests were observed following vaccination, the higher cycle thresholds, repeat negative tests, and inability to culture virus raise questions about their clinical significance.

Funder

Mass General Brigham and the Massachusetts General Hospital

Massachusetts Consortium on Pathogen Readiness

Harvard Center for AIDS Research

NIH

Broad Institute Viral Genomics Group

Centers for Disease Control and Prevention

National Institute of Allergy and Infectious Diseases

National Heart, Lung, and Blood Institute

Publisher

Oxford University Press (OUP)

Subject